Clinical Trials
51 trialsTACTAL
Baylor College of Medicine
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Alliance for Clinical Trials in Oncology
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
The First Affiliated Hospital of Soochow University
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
M.D. Anderson Cancer Center
PlaTform
The Lymphoma Academic Research Organisation
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
The First Affiliated Hospital of Soochow University
SEVENAZA
Gustave Roussy, Cancer Campus, Grand Paris
Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.
Ruijin Hospital
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
The First Affiliated Hospital of Soochow University
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Dragon
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Navy General Hospital, Beijing
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Medical University of South Carolina
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
University of Chicago
Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
The First Affiliated Hospital of Soochow University
CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).
The First Affiliated Hospital of Soochow University
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Weill Medical College of Cornell University
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
The First Affiliated Hospital of Soochow University
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)
The First Affiliated Hospital with Nanjing Medical University
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
Ruijin Hospital
VZCLLPI0146
Hackensack Meridian Health
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy
Ruijin Hospital
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
University of Virginia
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
Sun Yat-sen University
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Peking University
Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
Peking University
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Washington University School of Medicine
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
University of California, San Francisco
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
M.D. Anderson Cancer Center
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Washington University School of Medicine
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
EPIC
Seoul National University Hospital
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
Weill Medical College of Cornell University
Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)
Weill Medical College of Cornell University
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
University of Kentucky
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Duke University
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
M.D. Anderson Cancer Center
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center